-
1
-
-
0021337427
-
Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection
-
Neu HS: Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection. Am J Med 1984; 15:11-27
-
(1984)
Am J Med
, vol.15
, pp. 11-27
-
-
Neu, H.S.1
-
2
-
-
33750988183
-
Antibiotics past, present, and future
-
Khardori N: Antibiotics Past, present, and future. Med Clin North Am 2006; 90: 1049-1076
-
(2006)
Med Clin North Am
, vol.90
, pp. 1049-1076
-
-
Khardori, N.1
-
3
-
-
0032765427
-
Correlation between consumption of antimicrobials in humans and development of resistance in bacteria
-
Cristino JM: Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. Int J Antimicrob Agents 1999; 12:199-202
-
(1999)
Int J Antimicrob Agents
, vol.12
, pp. 199-202
-
-
Cristino, J.M.1
-
4
-
-
34548225858
-
Consumer antibacterial soaps: Effective or just risky?
-
Aiello AE, Larson EL, Levy SB: Consumer antibacterial soaps: Effective or just risky? Clin Infect Dis 2007; 45(Suppl 2):S137-S147
-
(2007)
Clin Infect Dis
, vol.45
, Issue.SUPPL. 2
-
-
Aiello, A.E.1
Larson, E.L.2
Levy, S.B.3
-
5
-
-
23244442660
-
Hospital and community fluoroquinolone use and resistance in Staphylococcus Aureus and escherichia coli in 17 US hospitals
-
MacDougall C, Powell JP, Johnson K, et al: Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005; 41:435-440
-
(2005)
Clin Infect Dis
, vol.41
, pp. 435-440
-
-
MacDougall, C.1
Powell, J.P.2
Johnson, K.3
-
6
-
-
38449092874
-
Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus Aureus and Pseudomonas Aeruginosa isolates from 47 French hospitals
-
Rogues AM, Dumartin C, Venier AG, et al: Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007; 28:1389-1395
-
(2007)
Infect Control Hosp Epidemiol
, vol.28
, pp. 1389-1395
-
-
Rogues, A.M.1
Dumartin, C.2
Venier, A.G.3
-
7
-
-
33644909052
-
Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus Aureus infection by encouraging decreased fluoroquinolone use
-
Madaras-Kelly KJ, Remington RE, Lewis PG, et al: Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol 2006; 27:155-169
-
(2006)
Infect Control Hosp Epidemiol
, vol.27
, pp. 155-169
-
-
Madaras-Kelly, K.J.1
Remington, R.E.2
Lewis, P.G.3
-
8
-
-
33646912478
-
Fluoroquinolone-resistant Pseudomonas Aeruginosa: Assessment of risk factors and clinical impact
-
Gasink LB, Fishman NO, Weiner MG, et al: Fluoroquinolone-resistant Pseudomonas aeruginosa: Assessment of risk factors and clinical impact. Am J Med 2006; 119: 526.e19-e25
-
(2006)
Am J Med
, vol.119
-
-
Gasink, L.B.1
Fishman, N.O.2
Weiner, M.G.3
-
9
-
-
0033059706
-
Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents
-
Carmeli Y, Troileet N, Eliopoulous GM, et al: Emergence of antibiotic-resistant Pseudomonas aeruginosa: Comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379-1382
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1379-1382
-
-
Carmeli, Y.1
Troileet, N.2
Eliopoulous, G.M.3
-
10
-
-
0038708419
-
The effect of an antimicrobial restriction program on Pseudomonas Aeruginosa resistance to beta-lactams in a large teaching hospital
-
Regal RE, DePestel DD, VandenBussche HL: The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003; 23: 618-624
-
(2003)
Pharmacotherapy
, vol.23
, pp. 618-624
-
-
Regal, R.E.1
DePestel, D.D.2
VandenBussche, H.L.3
-
11
-
-
66149118585
-
Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa
-
Pakyz ALA, Oinonen M, Polk RE: Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:1983-1986
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 1983-1986
-
-
Pakyz, A.L.A.1
Oinonen, M.2
Polk, R.E.3
-
12
-
-
27744532776
-
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan
-
Hsueh PR, Chen WH, Luh KT: Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005; 26:463-472
-
(2005)
Int J Antimicrob Agents
, vol.26
, pp. 463-472
-
-
Hsueh, P.R.1
Chen, W.H.2
Luh, K.T.3
-
13
-
-
33749028483
-
Imipenem resistance among Pseudomonas Aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes
-
Lautenbach E, Weiner MG, Nahamkin I, et al: Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900
-
(2006)
Infect Control Hosp Epidemiol
, vol.27
, pp. 893-900
-
-
Lautenbach, E.1
Weiner, M.G.2
Nahamkin, I.3
-
14
-
-
0346100720
-
Risk factors for acquisition of imipenem-resistant Acinetobacter baumanii: A case-control study
-
Lee SO, Kim NJ, Choic SH, et al: Risk factors for acquisition of imipenem-resistant Acinetobacter baumanii: A case-control study. Antimicrob Agents Chemother 2004; 48: 224-228
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 224-228
-
-
Lee, S.O.1
Kim, N.J.2
Choic, S.H.3
-
15
-
-
53949085115
-
Association between antibiotic usage and subsequent colonization or infection of extensive drugresistant Acinetobacter Baumanii:A matched case-control study in intensive care units
-
Tsai HT, Wang JT, Chen CJ, et al: Association between antibiotic usage and subsequent colonization or infection of extensive drugresistant Acinetobacter baumanii:A matched case-control study in intensive care units. Diagn Microbiol Infect Dis 2008; 62: 298-305
-
(2008)
Diagn Microbiol Infect Dis
, vol.62
, pp. 298-305
-
-
Tsai, H.T.1
Wang, J.T.2
Chen, C.J.3
-
16
-
-
0036736403
-
Pharmacodynamics of cefepime in patients with gram-negative infections
-
Tam VH, McKinnon PS, Akins RL, et al: Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002; 50:425-428
-
(2002)
J Antimicrob Chemother
, vol.50
, pp. 425-428
-
-
Tam, V.H.1
McKinnon, P.S.2
Akins, R.L.3
-
17
-
-
0030067765
-
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
-
Benko AS, Cappelletty DM, Kruse JA, et al: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 1996; 40:691-695
-
(1996)
Antimicrob Agents Chemother
, vol.40
, pp. 691-695
-
-
Benko, A.S.1
Cappelletty, D.M.2
Kruse, J.A.3
-
18
-
-
0041778291
-
Steadystate plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia
-
Boselli E, Breilh D, Duflo F, et al: Steadystate plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe pneumonia. Crit Care Med 2003; 31: 2102-2106
-
(2003)
Crit Care Med
, vol.31
, pp. 2102-2106
-
-
Boselli, E.1
Breilh, D.2
Duflo, F.3
-
19
-
-
35848946597
-
Optimal dosing of piperacillin-tazobactam for the treatment of pseudomonas aeruginosa infections: Prolonged or continuous infusion?
-
Kim A, Sutherland CA, Kuti JL, et al: Optimal dosing of piperacillin-tazobactam for the treatment of pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy 2007; 27:1490-1497
-
(2007)
Pharmacotherapy
, vol.27
, pp. 1490-1497
-
-
Kim, A.1
Sutherland, C.A.2
Kuti, J.L.3
-
20
-
-
65649084153
-
Population pharmacokinetics of high-dose, prolonged infusion cefepime in adult critically ill patients with ventilator-associated pneumonia
-
Nicasio AM, Ariano RE, Zelenitsky SA, et al: Population pharmacokinetics of high-dose, prolonged infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53:1476-1481
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 1476-1481
-
-
Nicasio, A.M.1
Ariano, R.E.2
Zelenitsky, S.A.3
-
21
-
-
28844443170
-
Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of pseudomonas aeruginosa
-
Tam VH, Schilling AN, Neshat S, et al: Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:4920-4927
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 4920-4927
-
-
Tam, V.H.1
Schilling, A.N.2
Neshat, S.3
-
22
-
-
41649099025
-
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: A multicenter, randomized study
-
Chastre J, Wunderink R, Prokacimaer P, et al: Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilatorassociated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096
-
(2008)
Crit Care Med
, vol.36
, pp. 1089-1096
-
-
Chastre, J.1
Wunderink, R.2
Prokacimaer, P.3
-
23
-
-
49949099257
-
Antibiotic resistance - What's dosing got to do with it?
-
Roberts JA, Kruger P, Paterson DL, et al: Antibiotic resistance-What's dosing got to do with it? Crit Care Med 2008; 36:2433-2440
-
(2008)
Crit Care Med
, vol.36
, pp. 2433-2440
-
-
Roberts, J.A.1
Kruger, P.2
Paterson, D.L.3
-
24
-
-
0027161344
-
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
-
Forrest A, Mix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081
-
(1993)
Antimicrob Agents Chemother
, vol.37
, pp. 1073-1081
-
-
Forrest, A.1
Mix, D.E.2
Ballow, C.H.3
-
25
-
-
0031663388
-
Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis
-
Lipman J, Scribante J, Gous A, et al: Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42:2235-2239
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2235-2239
-
-
Lipman, J.1
Scribante, J.2
Gous, A.3
-
26
-
-
0031940776
-
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy
-
Thomas J, Forrest A, Bhavnani J, et al: Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 521-527
-
-
Thomas, J.1
Forrest, A.2
Bhavnani, J.3
-
27
-
-
0023119430
-
Clinical response to aminoglycoside therapy: The importance of peak concentration to minimal inhibitory concentration
-
Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: The importance of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99
-
(1987)
J Infect Dis
, vol.155
, pp. 93-99
-
-
Moore, R.D.1
Lietman, P.S.2
Smith, C.R.3
-
28
-
-
0023176033
-
Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance
-
Blaser J, Stone BB, Groner MC, et al: Comparative study with enoxacin and netilmicin in a pharmcodynamic model to determine the importance of ratio of peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-1060
-
(1987)
Antimicrob Agents Chemother
, vol.31
, pp. 1054-1060
-
-
Blaser, J.1
Stone, B.B.2
Groner, M.C.3
-
29
-
-
0031829599
-
PharmacodynamicAntibiotics alone and in combination
-
Schentag J, Meagher A, Forrest J: Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998; 27:40-46
-
(1998)
Clin Infect Dis
, vol.27
, pp. 40-46
-
-
Schentag, J.1
Meagher, A.2
Forrest, J.3
-
30
-
-
0035577355
-
Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates
-
El Amari E, Chamot E, Auckenthaler R, et al: Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33:1859-1864
-
(2001)
Clin Infect Dis
, vol.33
, pp. 1859-1864
-
-
El Amari, E.1
Chamot, E.2
Auckenthaler, R.3
-
31
-
-
21844464306
-
Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials
-
Bliziotis I, Samonis G, Vardakas K, et al: Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-158
-
(2005)
Clin Infect Dis
, vol.41
, pp. 149-158
-
-
Bliziotis, I.1
Samonis, G.2
Vardakas, K.3
-
32
-
-
77950189404
-
-
Available at Accessed October 29
-
Centers for Disease Control and Prevention: Campaign to prevent antimicrobial resistance in healthcare settings. Available at: http://www.cdc.gov/drugresistance/healthcare. Accessed October 29, 2009
-
(2009)
Centers for Disease Control and Prevention
-
-
-
33
-
-
33846153776
-
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
-
Dellit TH, Owens RC, McGowan JE, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177
-
(2007)
Clin Infect Dis
, vol.44
, pp. 159-177
-
-
Dellit, T.H.1
Owens, R.C.2
McGowan, J.E.3
-
34
-
-
37549020378
-
Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008
-
Dellinger RP, Levy MM, Carlet JM, et al: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327
-
(2008)
Crit Care Med
, vol.36
, pp. 296-327
-
-
Dellinger, R.P.1
Levy, M.M.2
Carlet, J.M.3
-
35
-
-
13644269309
-
Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia
-
American Thoracic Society and the Infectious Diseases Society of America
-
American Thoracic Society and the Infectious Diseases Society of America: Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
-
(2005)
Am J Respir Crit Care Med
, vol.171
, pp. 388-416
-
-
-
36
-
-
66949140382
-
Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 update by the Infectious Diseases Society of America
-
Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and management of intravascular catheterrelated infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45
-
(2009)
Clin Infect Dis
, vol.49
, pp. 1-45
-
-
Mermel, L.A.1
Allon, M.2
Bouza, E.3
-
38
-
-
34548164363
-
De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate
-
Giantsou E, Liratzopoulos N, Efraimidou E, et al: De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007; 33:1533-1540
-
(2007)
Intensive Care Med
, vol.33
, pp. 1533-1540
-
-
Giantsou, E.1
Liratzopoulos, N.2
Efraimidou, E.3
-
39
-
-
67650576613
-
Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia
-
Swanson JM, Wood GC, Croce MA, et al: Utility of preliminary bronchoalveolar lavage results in suspected ventilator-associated pneumonia. J Trauma 2008; 65:1271-1277
-
(2008)
J Trauma
, vol.65
, pp. 1271-1277
-
-
Swanson, J.M.1
Wood, G.C.2
Croce, M.A.3
-
40
-
-
27144463065
-
Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results
-
Kollef MH, Kollef KE: Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-2713
-
(2005)
Chest
, vol.128
, pp. 2706-2713
-
-
Kollef, M.H.1
Kollef, K.E.2
-
41
-
-
2442589404
-
A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia
-
Micek ST, Ward S, Fraser VJ, et al: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799
-
(2004)
Chest
, vol.125
, pp. 1791-1799
-
-
Micek, S.T.1
Ward, S.2
Fraser, V.J.3
-
42
-
-
2942748293
-
The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures
-
Croce MA, Fabian TC, Mueller EW, et al: The appropriate diagnostic threshold for ventilator-associated pneumonia using quantitative cultures. J Trauma 2004; 56:931-936
-
(2004)
J Trauma
, vol.56
, pp. 931-936
-
-
Croce, M.A.1
Fabian, T.C.2
Mueller, E.W.3
-
43
-
-
0042821718
-
Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage
-
Miller PR, Meredith JW, Change MC: Optimal threshold for diagnosis of ventilator-associated pneumonia using bronchoalveolar lavage. J Trauma 2003; 55:263-268
-
(2003)
J Trauma
, vol.55
, pp. 263-268
-
-
Miller, P.R.1
Meredith, J.W.2
Change, M.C.3
-
44
-
-
8544252455
-
Deescalation therapy in ventilator-associated pneumonia
-
Rello J, Vidaur L, Sandiumenge A, et al: Deescalation therapy in ventilator-associated pneumonia. Crit Care Med 2004; 32: 2183-2190
-
(2004)
Crit Care Med
, vol.32
, pp. 2183-2190
-
-
Rello, J.1
Vidaur, L.2
Sandiumenge, A.3
-
45
-
-
33646471520
-
Clinical characteristics and treatment patterns among patients with ventilatorassociated pneumonia
-
Kollef MH, Morrow LE, Niederman MS, et al: Clinical characteristics and treatment patterns among patients with ventilatorassociated pneumonia. Chest 2006; 129: 1210-1218
-
(2006)
Chest
, vol.129
, pp. 1210-1218
-
-
Kollef, M.H.1
Morrow, L.E.2
Niederman, M.S.3
-
46
-
-
0034979537
-
Experience with a clinical guideline for the treatment of ventilator-associated pneumonia
-
Ibrahim EH, Ward S, Sherman G, et al: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115
-
(2001)
Crit Care Med
, vol.29
, pp. 1109-1115
-
-
Ibrahim, E.H.1
Ward, S.2
Sherman, G.3
-
47
-
-
0345283255
-
Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial
-
Chastre J, Wolff M, Fagon JY, et al: Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-2598
-
(2003)
JAMA
, vol.290
, pp. 2588-2598
-
-
Chastre, J.1
Wolff, M.2
Fagon, J.Y.3
-
48
-
-
38949118024
-
Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia
-
Mueller EW, Croce MA, Boucher BA, et al: Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma 2007; 63:1329-1337
-
(2007)
J Trauma
, vol.63
, pp. 1329-1337
-
-
Mueller, E.W.1
Croce, M.A.2
Boucher, B.A.3
-
49
-
-
0037074188
-
Treatment and outcome of Staphylococcus Aureus bacteremia: A prospective study of 278 cases
-
Jensen AG, Wachmann CH, Espersen F, et al: Treatment and outcome of Staphylococcus aureus bacteremia: A prospective study of 278 cases. Arch Intern Med 2002; 162:25-32
-
(2002)
Arch Intern Med
, vol.162
, pp. 25-32
-
-
Jensen, A.G.1
Wachmann, C.H.2
Espersen, F.3
-
50
-
-
62449183879
-
Therapeutic drug monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists
-
Rybak MJ, Lomaestro BM, Rotscahfer JC, et al: Therapeutic drug monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 82-98
-
-
Rybak, M.J.1
Lomaestro, B.M.2
Rotscahfer, J.C.3
-
51
-
-
23044433603
-
Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy
-
Bond CA, Raehl CL: Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J HealthSyst Pharm 2005; 62:1596-1605
-
(2005)
Am J HealthSyst Pharm
, vol.62
, pp. 1596-1605
-
-
Bond, C.A.1
Raehl, C.L.2
-
54
-
-
23844497745
-
Strategies to prevent antimicrobial resistance in the intensive care unit
-
Kollef MH, Micek ST: Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33:1845-1853
-
(2005)
Crit Care Med
, vol.33
, pp. 1845-1853
-
-
Kollef, M.H.1
Micek, S.T.2
-
55
-
-
0038468770
-
Routine cycling of antimicrobial agents as an infection-control measure
-
Fridkin SK: Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 2003; 36:1438-1444
-
(2003)
Clin Infect Dis
, vol.36
, pp. 1438-1444
-
-
Fridkin, S.K.1
-
56
-
-
45249099998
-
Increase in adult clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005
-
Zilberberg MD, Shorr AF, Kollef MH: Increase in adult clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14:929-931
-
(2008)
Emerg Infect Dis
, vol.14
, pp. 929-931
-
-
Zilberberg, M.D.1
Shorr, A.F.2
Kollef, M.H.3
-
57
-
-
58749095113
-
Strategies to prevent Clostridium Difficile infections in acute care hospitals
-
Dubberke ER, Gerding DN, Classen D, et al: Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29:S81-S92
-
(2008)
Infect Control Hosp Epidemiol
, vol.29
-
-
Dubberke, E.R.1
Gerding, D.N.2
Classen, D.3
-
58
-
-
35748932057
-
Safety concerns with fluoroquinolones
-
Mehlhorn AJ, Brown DA: Safety concerns with fluoroquinolones. Ann Pharmacother 2007; 14:1859-1866
-
(2007)
Ann Pharmacother
, vol.14
, pp. 1859-1866
-
-
Mehlhorn, A.J.1
Brown, D.A.2
-
59
-
-
55249105923
-
Clostridium difficileMore difficult than ever
-
Kelly CP, LaMont JT: Clostridium difficileMore difficult than ever. N Engl J Med 2008; 359:1932-1940
-
(2008)
N Engl J Med
, vol.359
, pp. 1932-1940
-
-
Kelly, C.P.1
LaMont, J.T.2
-
60
-
-
0032526223
-
Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficileassociated diarrhea and cost
-
Climo MW, Israel DS, Wong ES, et al: Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficileassociated diarrhea and cost. Ann Intern Med 1998; 128:989-995
-
(1998)
Ann Intern Med
, vol.128
, pp. 989-995
-
-
Climo, M.W.1
Israel, D.S.2
Wong, E.S.3
-
61
-
-
61849140052
-
Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital
-
Kallen AJ, Thompson A, Ristaino P, et al: Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol 2009; 30: 264-272
-
(2009)
Infect Control Hosp Epidemiol
, vol.30
, pp. 264-272
-
-
Kallen, A.J.1
Thompson, A.2
Ristaino, P.3
-
62
-
-
33847273700
-
Pharmacodynamic target attainment of six betalactams and two fluoroquinolones against Pseudomonas aeruginosaAcinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States Intensive Care Unites in 2004
-
DeRyke CA, Kuti JL, Nicolau DP: Pharmacodynamic target attainment of six betalactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States Intensive Care Unites in 2004. Pharmacotherapy 2007; 27:333-342
-
(2007)
Pharmacotherapy
, vol.27
, pp. 333-342
-
-
DeRyke, C.A.1
Kuti, J.L.2
Nicolau, D.P.3
-
63
-
-
60549098868
-
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
-
Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535
-
(2009)
Clin Infect Dis
, vol.48
, pp. 503-535
-
-
Pappas, P.G.1
Kauffman, C.A.2
Andes, D.3
-
64
-
-
56049120807
-
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
-
Labelle AG, Micek ST, Roubinian N, et al: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967-2972
-
(2008)
Crit Care Med
, vol.36
, pp. 2967-2972
-
-
Labelle, A.G.1
Micek, S.T.2
Roubinian, N.3
|